The company developed anti-endoglin antibodies and PD-L1 inhibitor candidates for oncology applications including sarcoma, renal cell carcinoma, and glioblastoma. After clinical trial setbacks in mid-2024, the company pursued liquidation rather than strategic alternatives.
Cyborg Score Rationale
Tracon ceased operations in late 2024 following clinical failure and delisting from NASDAQ. The company dissolved following stockholder approval in November 2024, rendering any forward-looking assessment moot.
Top Insights
(July 2024) Discontinued ENVASARC clinical trial; announced exploration of strategic alternatives
(July 2024) Delisted from NASDAQ after falling out of compliance with listing standards
(November 2024) Stockholders approved liquidation and dissolution plan with ~98% affirmative vote
Lead candidate was evafolimab, an anti-PD-L1 inhibitor that failed Phase II trials
Named Competitors
Jazz Pharmaceuticals — Specialty biopharmaceutical company focused on neuroscience and oncology
Sana Biotechnology — Cell therapy developer for cancer and genetic diseases
Kite Pharma — CAR-T cell therapy division of Gilead Sciences
Recent Developments
(July 2024) Terminated evafolimab trial and announced strategic alternatives review
(July 2024) Nasdaq delisting effective following noncompliance notification in June 2024
(November 2024) Stockholder approval of dissolution and liquidation plan
Open the full interactive Tracon Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.